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Background: Portal vein embolization (PVE) is performed to reduce the risk of liver failure and
subsequent mortality after major liver resection. Although a cut-off value of 2⋅7 per cent per min per
m2 has been used with hepatobiliary scintigraphy (HBS) for future remnant liver function (FRLF),
patients with perihilar cholangiocarcinoma (PHC) potentially benefit from an additional cut-off of 8⋅5
per cent/min (not corrected for body surface area). Since January 2016 a more liberal approach to PVE
has been adopted, including this additional cut-off for HBS of 8⋅5 per cent/min. The aim of this study
was to assess the effect of this approach on liver failure and mortality.
Methods: This was a single-centre retrospective study in which consecutive patients undergoing liver
resection under suspicion of PHC in 2000–2015 were compared with patients treated in 2016–2019,
after implementation of the more liberal approach. Primary outcomes were postoperative liver failure
(International Study Group of Liver Surgery grade B/C) and 90-day mortality.
Results: Some 191 patients with PHC underwent liver resection. PVE was performed in 6⋅4 per cent
(9 of 141) of the patients treated in 2000–2015 and in 32 per cent (16 of 50) of those treated in 2016–2019.
The 90-day mortality rate decreased from 16⋅3 per cent (23 of 141) to 2 per cent (1 of 50) (P= 0⋅009),
together with a decrease in the rate of liver failure from 19⋅9 per cent (28 of 141) to 4 per cent (2 of 50)
(P= 0⋅008). In 2016–2019, 24 patients had a FRLF greater than 8⋅5 per cent/min and no liver failure or
death occurred, suggesting that 8⋅5 per cent/min is a reliable cut-off for patients with suspected PHC.
Conclusion: The major decrease in liver failure and mortality rates in recent years and the simultaneous
increased use of PVE suggests an important role for PVE in reducing adverse outcomes after surgery
for PHC.
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Introduction
Radical resection of perihilar cholangiocarcinoma (PHC)
is the only treatment that offers a chance of long-term
survival1. Extended procedures, consisting of combined
liver and extrahepatic bile duct resection, are often
required, and are associated with high morbidity and
mortality rates2.
Mortality rates in Western series range from 6 to 18 per
cent3–5, whereas rates in Eastern series are lower, ranging
from 1 to 4 per cent6,7. Several studies have addressed
the particular differences in outcomes between these parts
of the world; along with several differences in treatment
strategy, the more frequent use of portal vein emboliza-
tion (PVE) in Eastern series was considered to be the
most striking difference2,8,9. Differences in the indication
for PVE appear to exist, as a recent study8 comparing the
present authors’ results with those of a large centre in Japan
showed that, although preoperative future remnant liver
volume shares were comparable between the two cohorts,
PVE was done in 55 per cent of the Eastern and 7 per cent
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of the Western patients. Of note, the indocyanine green
retention rate at 15min was used to assess liver function in
Japan, whereas in the present authors’ centre liver function
was assessed using hepatobiliary scintigraphy (HBS).
In recent years, strategies to select patients for PVE
have been developed that include other risk factors besides
future remnant liver volume and function using HBS10,11.
Although the cut-off value for future liver function was set
at 2⋅7 per cent per min per m2 in the general population of
patients undergoing major liver resection, this cut-off may
not be the same for all patients undergoing major liver
resection. The work-up of patients with PHC for resection
is known to be complex, specifically related to preoperative
biliary drainage, and postoperative outcomes are generally
worse compared with those following other indications for
major liver resection. Therefore, this subgroup of patients
requires a different approach compared with that used
for patients who undergo resection for colorectal liver
metastases, for example. Based on previously published
receiver operating characteristic (ROC) curve analysis
of the 2000–2015 cohort, a cut-off of 8⋅5 per cent/min
resulted in the best predictive value for patients with
PHC11. In that study, the correction for body surface area
(BSA) seemed not to increase the predictive value of future
liver remnant function (FLRF) for liver failure, leading to
an uncorrected cut-off with regard to BSA. Therefore, an
additional cut-off for FLRF of 8⋅5 per cent/min in patients
with PHC was added to the authors’ strategy11. These
studies have resulted in an altered treatment strategy, using
a more liberal approach to PVE in an attempt to improve
postoperative outcomes by reducing the risk of liver fail-
ure. However, the preoperative work-up of patients with
PHC can be challenging and, although PVE is considered
a safe and effective procedure, surgical resection is not
attained in all patients undergoing PVE12.
This study aimed to assess the effect of the more liberal
approach to PVE on postoperative outcomes, in particular
postoperative liver failure and mortality.
Methods
All consecutive patients who had surgical resection with
suspected PHC between January 2000 and October 2019
at the AcademicMedical Centre of AmsterdamUMCwere
included in the study. Data were obtained retrospectively
from a maintained database. Patient management and
work-up have been described in detail previously11,13,14.
HBS is the current modality of choice for remnant liver
assessment, and liver volumes are determined only when
there is a discrepancy in the results obtained by HBS or
at the surgeon’s request. Since the report on the effect
of preoperative liver function on postoperative outcomes
comprising the 2000–2015 cohort, the policy for appli-
cation of PVE was changed. From 2016 the new cut-off
without correction for BSA for liver function of 8⋅5 per
cent/min was adopted for patients with PHC based on the
ROC curves of the previously published study11. In the
present study, the latter cut-off value was therefore used.
All patients with PHC undergoing PVE between 2000
and 2019 were identified, regardless of whether or not they
underwent resection. The need for ethical approval and
individual informed consent was waived by the Institutional
Medical Ethics Committee (W19_114).
Primary outcomes
The primary outcomes of the present study were postop-
erative liver failure and mortality. Liver failure was defined
and graded according to the International Study Group of
Liver Surgery (ISGLS) criteria15, with only grades B and
C considered as clinically relevant. Postoperative mortality
was defined as death within 90 days of surgery.
Variables
Major liver resection was defined as the resection of at least
three Couinaud liver segments (with or without segment I).
All postoperative complications within 30 days of surgery
were scored and graded according to the Clavien–Dindo
classification16. Biliary leakage and postoperative haemor-
rhage were scored and graded according to the respective
ISGLS criteria, and only grades B and C were considered
clinically relevant15,17. Patients undergoing PVE who did
not reach surgical resectionwere identified, and the reasons
for not undergoing resection were recorded. Preoperative
cholangitis was defined as an episode of fever, leucocyto-
sis or raised C-reactive protein level, and malaise requiring
additional biliary drainage before resection18.
Statistical analysis
Categorical variables are presented as numbers with per-
centages and tested using either the χ2 or Fisher’s exact
test. Continuous variables that followed a normal distribu-
tion are presented as mean(s.d.) values and compared with
Student’s t test. Continuous variables that did not follow a
normal distribution are presented as median (i.q.r.) values
and tested using the Mann–Whitney U test. Two-tailed
P< 0⋅050 was considered statistically significant. All sta-
tistical analyses were performed with SPSS® version 25
(IBM, Armonk, New York USA) and figures were gener-
ated using GraphPad Prism® version 7 (GraphPad, La
Jolla, California, USA).
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Table 1 Baseline patient and disease characteristics
2016–2019
(n=50)
2000–2015
(n=141) P‡
Age (years)* 65(11) 63(10) 0⋅231§
Sex ratio (F :M) 21 : 29 53 : 88 0⋅582
BMI (kg/m2)† 23 (22–26) 22 (20–26) 0⋅974¶
ECOG performance status 0⋅285
0 30 (60) 98 (69⋅5)
1 13 (26) 35 (24⋅8)
2 6 (12) 7 (5⋅0)
3 1 (2) 1 (0⋅7)
ASA grade 0⋅190
I 5 (10) 30 (21⋅3)
II 37 (74) 88 (62⋅4)
III 8 (16) 23 (16⋅3)
Jaundice at presentation 33 (66) 104 (73⋅8) 0⋅295
Biliary drainage 36 (72) 123 (87⋅2) 0⋅013
Type of biliary drainage 0⋅242
Percutaneous transhepatic 5 (14) 11 (8⋅9)
Endoscopic 23 (64) 67 (54⋅5)
Both 8 (22) 45 (36⋅6)
Preoperative cholangitis 23 (46) 47 (33⋅3) 0⋅101
Bismuth type 0⋅134
I 0 (0) 0 (0)
II 0 (0) 4 (2⋅8)
IIIA 33 (66) 70 (49⋅6)
IIIB 9 (18) 44 (31⋅2)
IV 8 (16) 23 (16⋅3)
Portal vein embolization 16 (32) 9 (6⋅4) <0⋅001
Resection type 0⋅432
Left hemihepatectomy 17 (34) 57 (40⋅4)
Extended left hemihepatectomy 2 (4) 6 (4⋅3)
Right hemihepatectomy 16 (32) 33 (23⋅4)
Extended right hemihepatectomy 15 (30) 40 (28⋅4)
Central/minor liver resection 0 (0) 5 (3⋅5)
Portal vein reconstruction 8 (16) 38 (27⋅0) 0⋅120
Values in parentheses are percentages unless indicated otherwise; val-
ues are *mean(s.d.) and †median (i.q.r.). ECOG, Eastern Cooperative
Oncology Group. ‡χ2 or Fisher’s exact test, except §Student’s t test and
¶Mann–Whitney U test.
Results
A total of 215 patients were included in the study; 164 (76⋅3
per cent) were operated on in 2000–2015 and the remain-
ing 51 (23⋅7 per cent) between January 2016 and Octo-
ber 2019. Twenty-four patients who underwent external
bile duct resection without liver resection were excluded
from the analysis regarding PVE and liver volume and
function. Baseline patient and operative characteristics of
the 191 patients who had concomitant liver resection are
shown in Table 1. The characteristics of the two cohorts
from 2000–2015 (141 patients) and 2016–2019 (50) were
Table 2 Postoperative outcomes after liver resection
2016–2019
(n=50)
2000–2015
(n=141) P*
Major morbidity (Clavien–Dindo
grade≥ IIIA)
26 (52) 82 (58⋅2) 0⋅451
Liver failure (grade B/C) 2 (4) 28 (19⋅9) 0⋅008
Biliary leakage (grade B/C) 16 (32) 45 (31⋅9) 0⋅991
Bleeding (grade B/C) 2 (4) 12 (8⋅5) 0⋅293
Drainage of intra-abdominal
abscess
17 (35) 56 (39⋅7) 0⋅534
90-day mortality 1 (2) 23 (16⋅3) 0⋅009
Values in parentheses are percentages. *χ2 or Fisher’s exact test.
similar, although a higher proportion of patients in the later
cohort had no biliary drainage: 14 of 50 (28 per cent) versus
18 of 141 patients in the earlier cohort (P= 0⋅013). Type
of biliary drainage (endoscopic, percutaneous, or both)
did not differ significantly between the groups (P= 0⋅242).
Preoperative cholangitis appeared to occur more often in
the 2016–2019 cohort: 23 of 50 (46 per cent) versus 47 of
141 (33⋅3 per cent) in the 2000–2015 cohort (P= 0⋅101).
Portal vein embolization
Of the 191 patients who underwent liver resection, 25 (13⋅1
per cent) had preoperative PVE. PVEwas done in nine (6⋅4
per cent) of the 141 patients treated before 2016 and in 16
(32 per cent) of the 50 treated later (P< 0⋅001). Postoper-
ative outcomes for patients undergoing liver resection in
both time frames are shown in Table 2. There was a reduc-
tion in the rate of liver failure, from 19⋅9 per cent (28 of
141) in 2000–2015 to 4 per cent (2 of 50) in 2016–2019
(P= 0⋅008). The reduction in liver failure was accompanied
by a decreased 90-daymortality rate, from 16⋅3 per cent (23
of 141) to 2 per cent (1 of 50) (P= 0⋅009).
The largest liver resections associated with the highest
risk of liver failure are generally right liver resections and,
as expected, the use of PVE in patients undergoing either a
right or extended right hepatectomy increased from nine
of 73 (12 per cent) in the earlier cohort to 16 of 31
(52 per cent) in the later cohort (P< 0⋅001). Liver failure
and mortality had not generally decreased over time, but
markedly dropped from 2016 (Fig. 1), coinciding with the
more liberal policy in the use of PVE.
Liver function
Based on a study performed in the authors’ department11,
a specific cut-off of 8⋅5 per cent/min appeared safer for
patients with PHC with a negative predictive value of
94% compared to the general cut-off of 2⋅7 per cent per
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Fig. 1 Evolution of liver failure and mortality rates over time
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min per m2 with a negative predictive value of 82% in
the 2000–2015 cohort. In the 2016–2019 cohort, future
remnant liver function (FRLF) data were available for 49
of the 50 patients. Twenty-four of these 49 patients had a
baseline FRLF of 8⋅5 per cent/min or higher (3 after PVE),
and none had postoperative liver failure or died. Among
the 25 patients with FRLF below 8⋅5 per cent/min, two
developed liver failure (Fig. 2).
In the 2016–2019 cohort, 43 of the 49 patients had
preoperative remnant liver function above the general
cut-off of 2⋅7 per cent per min per m2. Ten of these 43
patients underwent PVE to reach this cut-off value for
liver function; one of them experienced fulminant post-
operative liver failure leading to death within 90 days of
surgery. Although the outcome was fatal in only one of
these 43 patients, these findings suggest that the 2⋅7 per
cent per min per m2 cut-off was insufficient in this group
of high-risk patients with PHC (Fig. 2).
Six patients underwent resection with a remnant liver
function below 2⋅7 per cent per min per m2, of whom three
had undergone PVE. The other three patients, without
PVE, all had a favourable postoperative course. Although
considered in these patients, PVE was not performed
owing to their expected low risk; none had experienced
preoperative cholangitis and two patients did not need
biliary drainage. Of the three patients who did have PVE,
one recovered from grade B liver failure. In the other two
patients PVE did not result in a remnant liver function
above 2⋅7 per cent per min per m2 or 8⋅5 per cent/min,
but they had a resection despite the higher risk as no
curative alternative was available after already having
undergone PVE.
There were ten patients who underwent PVE, but
with no subsequent surgical resection. In seven of these
patients unresectability was determined during explo-
rative laparotomy, owing to positive distant (N2) lymph
Fig. 2 Remnant liver function in patients with and without liver failure in the 2000–2015 and 2016–2019 cohorts
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nodes (3 patients), distant metastases (1), extensive vascular
involvement (2) and severemain portal vein thrombosis (1).
In two patients follow-upCTperformed after PVE showed
liver metastases, and in one patient resection was cancelled
due to an insufficient hypertrophy response after PVE.
Discussion
In this single-centre study of a large cohort of patients
undergoing resection for suspected PHC, the rates of liver
failure and 90-day mortality decreased from 19⋅9 and 16⋅3
per cent in 2000–2015 to 4 and 2 per cent respectively in
2016–2019. This major drop in adverse events coincided
with the increased use of PVE in the later cohort of up to
32 per cent, comparedwith only 6⋅4 per cent in 2000–2015.
PVE was first reported19 about 30 years ago, and has
since evolved into the standard procedure for preopera-
tive enhancement of the future remnant liver, reducing the
risk of liver failure and mortality12. PVE is most effective
in combination with compromised liver parenchyma20. As
most patients with PHC suffer from longstanding cholesta-
sis and usually require extensive liver resection, high rates
of PVE may be expected. Many Eastern series21,22 indeed
report frequent use of PVE of up to 60 per cent, in contrast
to most Western series10,23,24 that use PVE in only 4–24
per cent of patients.
In a recent direct comparison8 of the present cohort with
a large series from Japan, the differential use of PVE across
the globe was demonstrated, with a rate of 7 per cent (14
of 210) in the West compared with 54⋅9 per cent (90 of
164) in the East. This coincided with a halved mortality in
the East, although outcomes were similar after propensity
score matching, suggesting that use of PVE relates directly
to favourable outcomes8. These findings may explain the
higher operativemortality rate of 6–18 per cent inWestern
series4,5, compared with 1–4 per cent in the East2,6,7.
Preoperative cholangitis is a significant risk factor for
postoperative mortality5,24, and has been associated with
operative mortality rates of up to 25 per cent25. Generally,
in patients undergoing PVE, unilateral biliary drainage of
only the future remnant liver is undertaken. Preoperative
biliary drainage was increasingly omitted in patients with
a sufficient future remnant liver volume (above 40–50
per cent) or FRLF greater than 3⋅5 per cent per min per
m2, resulting in a lower percentage of biliary drainage
after 2015. In contrast, the rate of preoperative cholangitis
increased from 33⋅3 per cent before 2016 to 46 per cent
in patients operated on after 1 January 2016. PVE pro-
longs the duration of biliary drainage and thus negatively
influences the risk of cholangitis. However, although
cholangitis occurred in 46 per cent of the 2016–2019
cohort, the rates of liver failure and 90-day mortality
were low. This suggests that the benefits of PVE greatly
outweigh the risks of the longer time to surgery, along
with the risk of developing cholangitis. The high incidence
of cholangitis is likely to be explained by the liberal defini-
tion, which differs from other definitions that may require
a positive bile culture for example, as bile samples are not
always obtained (for instance with endoscopic drainage)24.
Based on findings in the 2000–2015 cohort, the sug-
gested remnant liver function for safe liver resection in
patients with PHC was adjusted from 2⋅7 per cent per
min per m2 to 8⋅5 per cent/min11. The previous analysis11
showed that use of the 2⋅7 per cent per min per m2 cut-off
still frequently resulted in liver failure in patients with
a function above the cut-off value. Therefore, a 8⋅5 per
cent/min cut-off (uncorrected for BSA) was devised, with
a high negative predictive value (94 per cent), meaning
that the risk of liver failure is very low when liver function
is measured above this value. The zero postoperative liver
failure and mortality rates in patients in the 2016–2019
cohort with a FRLF above 8⋅5 per cent/min confirmed that
resection can be undertaken safely in these patients. This
can therefore be considered a validation of this cut-off
value. Although not all patients below the 8⋅5 per cent/min
cut-off underwent PVE, it was considered for all these
patients, and the associated, more liberal, approach to PVE
resulted in improved outcomes. PVE can be omitted safely
in patients with a function above 8⋅5 per cent/min, whereas
PVE should be considered carefully in every patient with
a function below 8⋅5 per cent/min.
In the three patients who did not reach the 2⋅7 per cent
per min per m2 or 8⋅5 per cent/min cut-off after PVE, the
increased surgical risk was accepted and they did undergo
resection, as the alternative would have been palliation
with a dismal prognosis; other alternatives, such as ALPPS
(associated liver partition and portal vein ligation for
staged hepatectomy), are currently associated with unac-
ceptable outcomes26. A preliminary study27 examining
dual embolization of both the portal and hepatic vein
has shown promising results, and may help to induce a
large hypertrophic response in patients with a very small
remnant liver. Of the ten patients in the present study
who had PVE not followed by resection, the reason for
not proceeding to resection was the lack of a sufficient
hypertrophic response in only one patient, whereas in the
other patients the finding of advanced disease precluded
resection. In the later cohort a strict policy was applied that
precluded patients with a bilirubin level above 50 μmol/l
from undergoing HBS because of the competitive uptake
of mebrofenin with bilirubin, leading to potentially false
low assessments of functional capacity. This also enforced
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 449–455
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the policy of achieving complete biliary drainage of the
future liver remnant in patients with resectable PHC.
Using these changes in the work-up of patients, functional
assessment is now used mainly to guide preoperative
management, and volume assessment is no longer part of
standard practice in the authors’ institution.
This study has several limitations, mostly due to its retro-
spective nature. Although the study protocol was designed
prospectively following the analysis of the 2000–2015
cohort11, it was still subject to selection bias. The decrease
in liver failure coincided with the liberal implementation
of PVE, but it is possible that other unmeasured factors,
such as improved intraoperative or patient-specific factors,
influenced this association. However, no gradual decline
in liver failure and mortality was observed over time, as
would be expected with improved perioperative manage-
ment, but there was a sudden drop in liver failure and
mortality starting in 2016. In addition, the 141 patients
operated on between 2000 and 2015 were compared with
a smaller group of 50 patients treated between 2016 and
2019, within a much shorter time frame. In the future, a
comparison of two more equal groups is needed to confirm
these findings. The inclusion of multiple centres would
potentially enhance the validity of the analyses; however,
there is much improvement needed in the implementa-
tion ofHBS among centres treating these complex patients.
Notwithstanding these facts, the present study findings can
be considered a preliminary prospective validation of the
previous HBS analyses performed11. The structural appli-
cation of PVE in patients planned for extensive liver resec-
tion with low FRLF, and perhaps also in patients who had
preoperative cholangitis, potentially reduces adverse out-
comes and ultimately offers more patients the chance of
long-term survival.
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